Company Overview
Snapshot
Founded in January 2018 by Prof. David (Dedi) Meiri and Shmuel (Muli) Mandel, Cannasoul Analytics operates with 11–50 employees. The company has raised $4 million across two funding rounds. In November 2023, Synaptogenix acquired a significant stake in the company, marking a key strategic development.
Business overview
Cannasoul Analytics is an Israeli drug-discovery company focused on developing therapeutics derived from natural cannabis compounds. The company leverages a proprietary analytical platform and a data-driven approach, along with its clinical trial framework, to identify and develop active compounds. It has analyzed over 100 cannabinoids and 100 terpenes, serving the health tech and life sciences sectors, particularly in pharmaceuticals, medical cannabis, and biotechnology.
Strategic signal
In November 2025, InterCure and Cannasoul Analytics signed strategic investment and collaboration agreements to advance cannabis science and pharmaceutical innovation. This partnership signals a significant validation of Cannasoul's drug discovery capabilities and its potential to drive further advancements in the medical cannabis industry, indicating strong forward momentum for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is Cannasoul Analytics' core focus?
- Cannasoul Analytics is an Israeli drug-discovery company that develops therapeutics derived from natural cannabis compounds, utilizing a proprietary analytical platform to identify and develop active compounds.
- When was Cannasoul Analytics founded and by whom?
- Cannasoul Analytics was founded in January 2018 by Prof. David (Dedi) Meiri and Shmuel (Muli) Mandel.
- What was a significant recent partnership for Cannasoul Analytics?
- In November 2025, Cannasoul Analytics signed strategic investment and collaboration agreements with InterCure to advance cannabis science and pharmaceutical innovation.
- Which company acquired a stake in Cannasoul Analytics?
- In November 2023, Synaptogenix acquired a significant stake in Cannasoul Analytics.
- What was a notable collaboration for Cannasoul Analytics in 2020?
- In April 2020, Eybna and Cannasoul Analytics joined forces to prove a proprietary terpene formulation for treating viral infections via modulation of cytokine storm.